Report Overview

The global protein therapeutics market was valued at US$57 billion in 2005. Biotechnology has made notable inroads in the field of protein therapeutics, resulting in some of the key products presently available in the category. Recombinant proteins are potentially advantageous in terms of higher efficacy and fewer side effects than other pharmaceutical products, as they can be more specifically targeted to the cause of the disease, rather than the treatment of its symptoms.

This report examines each of the protein therapeutics classes in turn, assessing the market potential, and encompassing main therapeutic areas to which they are applicable.

The report assesses the overall protein therapeutics market, key classes, and the factors influencing their historical and future performance. The report provides an overview of key products in each category, comparing their clinical efficacy and marketing position. The overview of the current market is given in terms of segmentation by category, by region and by leading players and their products. Moreover, the report examines the promise of new drugs in each class and research and development efforts aimed at improving their delivery. Finally, the future performance of the protein therapeutics market as a whole is examined against the background of pricing, emerging generic competition and manufacturing issues, indicating the likely trends in the coming years, and identifying possible solutions for problematic issues.